立体定向磁共振引导自适应放疗用于非小细胞肺癌超中央转移灶的安全性与疗效
该回顾性研究分析11例非小细胞肺癌患者共18个超中央转移灶接受立体定向磁共振引导自适应放疗(SMART)的结果。中位剂量40 Gy分5-8次,全部治疗在屏气下完成且100%分次行在线计划自适应。未观察到≥3级毒性,1年局部无进展率93%,中位总生存20个月。
要点
- SMART治疗超中央NSCLC转移灶未出现≥3级毒性,安全性良好。
- 1年局部无进展率达93%,局部控制效果优异。
- 所有78个治疗分次均实现在线计划自适应,屏气下完成治疗。
核心结论
- SMART每日在线自适应在超中央NSCLC中实现优异的局部控制和良好的安全性,无严重毒性,与常规非自适应SABR相当。
研究设计与样本
- 回顾性研究分析2020至2023年11例组织学确诊NSCLC患者的18个超中央转移灶,接受SMART-based SABR。
- 超中央病灶定义为计划靶体积与近端支气管树、食管或肺血管重叠。
主要发现
- 中位剂量40 Gy(范围30-60 Gy),分5至8次,全部治疗在屏气下完成。
- 78个治疗分次中100%行在线计划自适应,未观察到≥3级毒性。
- 1至2级急性和晚期毒性发生率分别为54%和18%。
- 中位随访28个月(范围5-41个月),66.7%患者存活。
- 1年局部无进展率为93%,中位无进展生存5.8个月(范围1-39个月),中位总生存20个月(范围5-41个月)。
关键数值与推荐
- 超中央病灶定义:计划靶体积与近端支气管树、食管或肺血管重叠。
- 中位剂量40 Gy(范围30-60 Gy)分5至8次。
临床怎么用
- 对超中央NSCLC转移灶,SMART每日在线自适应可在屏气下实施并实现高局部控制且无严重毒性。
- 治疗中100%分次实现在线计划自适应,提示该技术流程可行。
局限性
- 回顾性研究,样本量小(11例患者18个病灶)。
- 中位随访28个月,部分患者随访时间较短(最短5个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic ablative radiation therapy (SABR) is a standard of care for early-stage lung cancer and thoracic oligometastatic or oligoprogressive disease. However, ultracentral lesions remain challenging because of their proximity to critical mediastinal structures and the associated risk of severe toxicity. Stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) allows for daily plan adaptation and real-time tracking in breath-hold, enhancing target coverage while improving sparing of adjacent organs compared to conventional SABR. METHODS AND MATERIALS: This retrospective study analyzed outcomes of SMART-based SABR for ultracentral metastatic lesions in patients with histologically confirmed non-small cell lung cancer (NSCLC). Ultracentral lesions were defined by planning target volume overlapping with the proximal bronchial tree, esophagus, or pulmonary vessels. Endpoints included grade ≥ 3 SMART-related toxicity, freedom from local progression, progression-free survival, and overall survival. RESULTS: Between 2020 and 2023, 11 patients with 18 ultracentral NSCLC lesions underwent SMART. All treatments were delivered in breath-hold. The median dose was 40 Gy (range, 30-60 Gy) in 5 to 8 fractions. Online plan adaptation was performed for 100% of the 78 delivered fractions. No grade ≥ 3 toxicities were observed. Rates of grade 1 to 2 acute and late toxicities were 54% and 18%, respectively. At a median follow-up of 28 months (range, 5-41 months), 66.7% of patients were alive. One-year freedom from local progression was 93%. Median progression-free survival was 5.8 months (range, 1-39 months), and median overall survival was 20 months (range, 5-41 months). CONCLUSIONS: SMART with daily online adaptation achieved excellent local control and a favorable safety profile in ultracentral NSCLC, comparable to conventional non-adaptive SABR, but without severe toxicity.
引用
- Moreno-Olmedo E, George B, Owczarczyk K, et al. Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2025. PMID: 41211609. doi:10.1016/j.adro.2025.101906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。